Apart from evaluating orbital inflammation in Graves' ophthalmopathy (GO) somatostatin (SST) analogues have been proposed as a therapy but recent trials were disappointing. We aimed to measure somatostatin receptor (SSTR) expression in orbital tissues ex vivo and determine whether the new broad-affinity analogue SOM230 might be of therapeutic use.
Introduction
Somatostatin (SST) analogues such as octreotide (OCT) have a wide application in clinical imaging. Somatostatin receptors (SSTR) are expressed in many tissues, including activated lymphocytes. Consequently OCT scintigraphy was proposed as a method to evaluate orbital inflammation in Graves' ophthalmopathy (GO), with the level of uptake correlating well with the clinical activity score (CAS) (7, 17) .
Subsequently it was suggested that SST analogues could provide a treatment for GO, with several studies reporting an improvement in CAS (9, 11) . However, in one of two recent double-blind, placebo-controlled trials no significant therapeutic effect of OCT long acting repeatable (LAR) was found in patients with moderate to severe GO (4) . In contrast, a second study reported an improvement in CAS (although the clinical benefits were questioned) and eyelid fissure was reduced (21) .
A further prospective randomized study (2) showed no difference in the CAS at 12 weeks between patients with active GO and controls treated with slow release induced cAMP production (14) . Subsequently the same group reported moderate to strong expression of all 5 SSTRs in lymphocytes obtained from GO orbits, in contrast to the equivalent peripheral blood mononuclear cells, which express only SSTRs 2, 3 & 4 (15) .
In recent years adipogenesis has been recognised as an important pathogenic mechanism in GO (3, 18) . A recent study has demonstrated that SST production is induced and SSTR expression modulated in adipocytes exposed to inflammatory stimuli such as IL-1 (20) . However, information regarding SST and SSTR expression during adipogenesis is lacking. Furthermore, SOM230, a synthetic SST analogue with high affinity across a wider range of SSTR subtypes (SSTR1, 2, 3 & 5), has recently been developed (12) , making a systematic evaluation of SSTR expression in GO orbits timely.
Materials & Methods

Patients Studied
For the QPCR studies adipose/connective tissue samples were obtained from a total of 23 patients with GO. The surgical procedures were orbital decompressions (n=17) and blepharoplasty (n=6). These comprised 21 women and 2 men, with a mean age of 47.2 yrs (range 18-77). They were compared with a group of 8 individuals free of thyroid or other inflammatory eye disease who underwent orbital decompression (n=4) or blepharoplasty (n=4). The controls were 6 women and 2 men with a mean age of 53.1 yrs (range 28-86). The majority of patients were Caucasian except for 2 Asians in each group.
There were 12 non-smokers and 11 smokers in the Graves' group and 4 non-smokers and 4 smokers in the control group.
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All GO patients except for two had inactive GO (CAS below 2) as documented by the examining ophthalmologists (24) . All GO patients had received systemic steroid treatment at some stage during their disease.
All samples were obtained with informed consent. The study was performed with appropriate Ethics Committee approval and was conducted in accordance with the principles of 'The Declaration of Helsinki'.
RNA extraction, DNAse treatment, Reverse Transcription
Orbital adipose/connective tissues were snap-frozen and stored at -80°C until use.
They were pulverized under liquid nitrogen and the RNA extracted using Trizol ® , according to the manufacturer's instructions. Following quantification, either 1 µg total RNA or 8 µl (when RNA concentrations were measurable but below 125ng/µl) were treated with DNAse (1U; Promega) in a total volume of 10µl. Subsequently, depending on the concentration of the input RNA 1 (>200ng/ul) or 2 µl (<200ng/ul) were reverse transcribed, in a total volume of 20µl, with MMLV reverse transcriptase (0.1U; Promega) using standard protocols (19) .
Depending on the amount of RNA extracted, 3 -6 reverse transcription reactions were performed for each sample; care was taken that individual Q-PCR experiments (please see below) always used cDNA generated in the same batch.
Preparation of plasmid standards; optimization of standard curves & Q-PCR
The five SSTR are intronless genes. Consequently we were able to amplify fragments of each subtype from genomic DNA, in a PCR reaction, using standard protocols (19) .
All primers (designed with Primer 3 software) used are shown in table 1.
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Gene
Forward primer  Reverse primer  SSTR1 TGAGTCAGCTGTCGGTCATC  GCGGTGGCGTAATAGTAAC  SSTR2  GGCCAATCTTCCTCTTTTCC  TGGTTTGAGGTGTTGGTTGA  SSTR3 CTGGGTAACTCGCTGGTCAT  CAGGCAGAATATGCTGGTGA  SSTR4  ACCAGCGTCTTCTGTCTCA  ACACGCCCAGGTTGATGAG  SSTR5 TCATCTGCCTGTGCTACCTG  GGAGAGGATGACCACGAAGA  CD3 CGCCTTCAACAACAGCATTA GATTAAACCCGGCCACTTTC APRT GCTGCGTGCTCATCCGAAAG CCTTAAGCGAGGTCAGCTCC Table 1 . Primers for Somatostatin receptor subtypes; chain lymphocyte marker (CD3 ) and adenosine phosphoribosyl transferase housekeeper gene (APRT).
The PCR fragments were subcloned into pGEM-T according to the manufacturer's instructions and the plasmid identity was confirmed by sequencing. Q-PCR was conducted using SYBR Green incorporation measured on a Stratagene MX 3000.
Each reaction comprised 1µl plasmid standard containing 10 6 to 10 2 copies, in a total volume of 25µl. Initially the optimal primer combination, to generate a homogeneous amplification peak in the absence of primer dimers, was determined for each subtype. Microscopic examination provided a means of determining whether morphological changes which accompany adipogenesis, e.g. rounding-up of cells and/or acquisition of lipid filled droplets, had occurred. The degree of adipogenesis was also evaluated by measuring transcripts for the adipocyte differentiation markers C/EBP , PPAR , and LPL as previously described (25) . Briefly the various cell populations were plated in 6 well plates in complete or differentiation medium, supplemented or not with analogue. Fourteen days later, RNA was extracted, reverse transcribed and transcript copy numbers measured using SYBR Green and a Stratagene MX3000 light cycler.
Standard curves (the PCR amplicon subcloned into pGEM-T at 10 6 to 10 2 copies)
were included for each gene and results are expressed as an absolute value, either per microgram of input mRNA or relative to the housekeeping gene APRT.
A possible effect of TSHR activation on SSTR expression was examined. Activating mutant TSHR, L629F and M453T, and the WT TSHR were introduced into the orbital preadipocytes (2 of the GO and 1 normal) using retroviral vectors, previously produced in our laboratory (5) . Geneticin selection resulted in mixed populations stably expressing the various TSHR, which exhibit increased basal levels of cAMP compared with the equivalent non-modified cell population, all as previously described (25) . RNA was extracted from the non-modified and mutant TSHR expressing cells for measurement of SSTR transcripts. 
Results
SSTR1 is over expressed in all & SSTR2 increased in a proportion of GO orbits
SSTR1 was detected and quantified in all samples; 144.6 transcripts/µg input RNA 
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Plotting the expression of SSTR1 against SSTR2 results showed that the expression of SSTR1 in GO samples and controls does not parallel the expression of SSTR2 (data not shown). There was no statistically significant difference in the expression of SSTR1 and 2 between smokers and non-smokers.
SSTR3, 4 & 5 are at the limit of detection
Transcripts for SSTR 3, 4 and 5 were undetectable in the majority of samples and even when they were present, were at the limit of detection. SSTR3 was detected in 10/23 GO and 6/8 normal orbital samples; SSTR4 in 2/23 and 0/9 and SSTR5 in 3/23 and 0/9 GO and normal orbital samples respectively.
Are SSTR transcripts derived from infiltrating lymphocytes or resident orbital cells?
Since lymphocytes have been reported to express SSTR (15) , and as lymphocytic infiltration is a feature of GO (13), we measured transcripts for the T cell receptor constant region CD3-to assess the lymphocyte contribution to SSTR expression.
The lymphocyte contribution was minimal, since transcripts for CD3-were at the limit of detection (LOD) in all 31 orbital samples tested ex vivo. This contrasted with Jurkatt lymphocyte cDNA, used as a positive control, in which >10 4 transcripts/µg input RNA were measured (data not shown).
Does TSHR activation influence SSTR expression?
Having established that the SSTR were expressed by orbital cells, we sought an explanation for the increased levels of SSTR1 and SSTR2 in some GO samples. The most severe GO correlates with Graves' patients having the highest titres of thyroid stimulating antibodies (8, 1) . We have previously reported that a small proportion of (25) . Examination of preadipocytes from two GO and one normal patient sample in this protocol revealed no consistent or significant change in the expression of any of the 5 SSTR subtypes.
Does adipogenesis provide an explanation for the increased expression of SSTR1 &2?
We and others have reported an increase in adipogenesis in GO orbits (23, 10) . We thus investigated whether this process affects SSTR expression. As shown in figure   2A , transcripts for SSTR1 and SSTR2 are increased in the process. The experiment was repeated, with or without DNAse treatment, with five different populations of GO preadipocytes and one normal control, all with similar results. We were also able to demonstrate that the transcript levels for SSTR1 reflect those of the protein, in a parallel western blot performed on samples taken at the same time points, as shown in figure 2B . Transcripts for SSTR 3, 4 & 5 were all at or below the limit of detection and were unchanged by adipogenesis.
SOM 230 produces significantly greater inhibition of orbital pre-adipocyte proliferation than Octreotide.
We compared the effects of SOM 230 and OCT on orbital preadipocyte proliferation 
Discussion
To our knowledge, this is the first report of SSTR expression in GO orbits analysed ex vivo and compared with tissue from normal controls. We find an upregulation in SSTR1 in the GO group as a whole and in SSTR2 in a proportion of the patients. Our However, since all of the receptors have a single exon, we were obliged to treat our samples with DNAse to avoid quantifying copies amplified from genomic DNA. Thus we may have missed differences in the expression levels of SSTR 3, 4 and 5. Since we did not detect transcripts for CD3-, which we have used as a marker of lymphocytic infiltration in the ex vivo samples, we assume that the SSTRs are expressed on the orbital preadipocyte/fibroblast population. The absence of lymphocytes may be expected in orbital tissue taken from individuals with inactive disease (as in 21/23 in the present study) and is probably the result of previous steroid therapy for immunosuppression.
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Our samples were derived from within the orbit and also from the eyelid, but no differences were found in the expression levels. Similarly when analyzing the data, taking into account the smoking status of the donor, no differences were apparent.
Thus smoking does not seem to modify the expression of SSTR Application of in vitro models to investigate the effects of TSHR activation and adipogenesis on SSTR expression levels produced opposing results. We did not find a consistent or significant change in the level of SSTR 1 and 2 expression in nonmodified orbital preadipocytes when compared with the same population expressing an activating mutant TSHR, thus we can eliminate a role for thyroid stimulating antibodies (which also result in TSHR activation) in this aspect of orbital biology. In contrast, we observed upregulation of SSTR1 and 2 during differentiation to mature adipocytes, suggesting that adipogenesis provides one explanation for the increased expression measured in the GO samples ex vivo. Furthermore, we were able to demonstrate that the transcript and protein levels of SSTR1 correlate and our subsequent proliferation studies using somatostatin analogues validate the functional relevance of these receptors.
We have previously reported (23) increased adipogenesis in GO orbits (compared with normal) in samples obtained from patients with inactive disease, (as in the current study) and this has been confirmed by others (10). Our findings suggest that even in apparently inactive disease, as defined by CAS, pathological mechanisms may still be in operation. The expression of SSTR1 did not correlate with that of SSTR2 in either GO patients or controls analysed ex vivo. Since both receptor subtypes are upregulated during adipogenesis, this indicates that additional mechanisms must be contributing to the increased expression, including the possibility that a fundamental difference exists in SSTR expression between GO preadipocytes and controls.
We then determined whether established and novel somatostatin analogues exerted an effect on the biological activity of the orbital preadipocyte/fibroblasts. As expected, the effects of OCT and SOM230 were very similar, with both inhibiting proliferation, although SOM230 had a significantly greater impact on proliferation than OCT.
Our attempts to define whether the reduced proliferation was caused by increased apoptosis or a block/prolongation of the cell cycle were not successful due to the combination of slow growth, large size of cells and limited availability. OCT has previously been shown to induce apoptosis in GO fibroblasts, accompanied by reduced Bcl-2 expression (15). Preliminary reports suggest that these findings are also replicable in GO fibroblasts treated with SOM230 (16).
In conclusion, we have examined expression of SSTR subtypes in GO orbital tissues 
